Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
4.370
+0.060 (1.39%)
At close: Apr 2, 2026, 4:00 PM EDT
4.450
+0.080 (1.83%)
After-hours: Apr 2, 2026, 7:49 PM EDT
Taysha Gene Therapies Revenue
In the year 2025, Taysha Gene Therapies had annual revenue of $9.77M with 17.28% growth. Taysha Gene Therapies had revenue of $5.49M in the quarter ending December 31, 2025, with 171.27% growth.
Revenue (ttm)
$9.77M
Revenue Growth
+17.28%
P/S Ratio
128.45
Revenue / Employee
$98,717
Employees
99
Market Cap
1.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.77M | 1.44M | 17.28% |
| Dec 31, 2024 | 8.33M | -7.12M | -46.07% |
| Dec 31, 2023 | 15.45M | 12.95M | 517.55% |
| Dec 31, 2022 | 2.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 1.12B |
| Pharming Group | 376.13M |
| Immatics | 56.67M |
| Wave Life Sciences | 42.73M |
| Zenas BioPharma | 10.00M |
| DBV Technologies | 5.64M |
| AtaiBeckley | 4.09M |
TSHA News
- 16 hours ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 22 days ago - Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19 - GlobeNewsWire
- 4 weeks ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 3 months ago - Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome - GlobeNewsWire
- 5 months ago - Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript - Seeking Alpha